Biogen (NASDAQ:BIIB) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Biogen (NASDAQ:BIIB) posted its quarterly earnings results on Wednesday. The biotechnology company reported $3.44 earnings per share for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01, Zacks reports. Biogen had a net margin of 16.81% and a return on equity of 14.98%. Biogen updated its FY 2025 guidance to 15.250-16.250 EPS.

Biogen Stock Performance

Shares of NASDAQ BIIB traded down $6.81 during mid-day trading on Wednesday, reaching $132.58. 1,346,606 shares of the company’s stock were exchanged, compared to its average volume of 1,287,285. The firm has a market capitalization of $19.32 billion, a price-to-earnings ratio of 11.90, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08. The firm has a 50-day moving average price of $148.28 and a two-hundred day moving average price of $174.33. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. Biogen has a 52 week low of $128.51 and a 52 week high of $238.00.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. TD Cowen dropped their price target on shares of Biogen from $300.00 to $275.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. BMO Capital Markets downgraded Biogen from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $230.00 to $164.00 in a research report on Friday, December 20th. Stifel Nicolaus cut Biogen from a “buy” rating to a “hold” rating and set a $175.00 price target on the stock. in a research report on Monday, December 16th. Oppenheimer cut their price objective on Biogen from $270.00 to $255.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Finally, Jefferies Financial Group lowered shares of Biogen from a “buy” rating to a “hold” rating and lowered their target price for the stock from $250.00 to $180.00 in a report on Monday, December 9th. Seventeen investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, Biogen presently has a consensus rating of “Hold” and a consensus price target of $221.65.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.